The pain-relieving effect of CGRP monoclonal antibodies is substantial in treating chronic inflammatory conditions (osteoarthritis, chronic low back pain, migraine or rheumatoid arthritis, etc.)[34]. This evidence concerns the gene CALCA and migraine disorder.